 FLORHAM PARK, N.J., July 30, 2020 GLOBE NEWSWIRE -- PDS Biotechnology Corporation Nasdaq: PDSB, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that the Company will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020, before the market opens. Following the release, Dr. Frank Bedu-Addo, Chief Executive Officer, Michael King, Interim Chief Financial Officer, and Dr. Lauren Wood, Chief Medical Officer will host a conference call to review the financial results and provide a business update. The conference call is scheduled to begin at 8:00 am ET on Thursday, August 13, 2020. Participants should dial 877-407-3088 United States or 201-389-0927 International and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Companys corporate website at the live webcast, the event will be archived on PDS Biotechs website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 United States or 201-612-7415 International with confirmation code 13707451.About PDS BiotechnologyPDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit or follow us on Twitter at PDSBiotech.Media Investor Relations Contact:Deanne Randolph PDS Biotech Phone: 1 908 517-3613 Email: Lobo The Ruth Group Phone: 1 646 536-7037 Email: 